1Rosen KS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase Ⅲ,double-blind, randomized trialthe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003,21:3150.
2Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med. 2002, 137(7) : 586.
3Gallowitsoh HJ,Kresnik E, Gasser J, etal. 18F fluorodeoxy glucoee positron - emission of tumor recurrence and metastases in the follow - up of patients with breast carcinoma: A comparison to conventional imaging. Invest Radiol. 2003, 38(5) :250.
4Gayed I, Vu T, Johnson M, et al. Comparison of bone and2-deoxy-^18 F fluoro - D - glucose positron emission tomography in the evalu - atlon of bony metastases in lung caner. Mol Imaging Biol. 2003,5(1):26.
5Uematsu T,Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. Am J Roentgenol. 2005, 184(4):1266.
6Gallowitsch HJ, Kresnik E, Gasser J, etal.^18F fluorodeoxyglucese positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow - up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radinl. 2003, 38(5) : 250.
7Resnick D. Skeletal metastasis. Resnick D. Diagnosis of bone and joint disorders. 4th ed. Philadephia:WB Saunder Co. 2002, 4274.
8Clohisy DR. Metastatic skeletal disease. Filzgarald RH, Kaufer H, Malkani A. Orthopaedies. London: Mosby Inc. 2002, 1078.
6Yahara J, Noguchi M, Noda S. Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systenic treatment. BJUInt, 2003Sep; 92 (4): 379
7Savelli G, Chiti A, Grasselli G, et al. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res, 2000, 20:1115
8Lissoni P, Vghi M, Ardiffoia A, et al. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to polactin secretion in heavily pretreated metastatic breast cancer. Newroendocrinol Lett. 2001, 22(1):27.
9DiCaprio MR,Friedlaender GE.Malignant bone tumors:limb sparing versus amputation[J].Orthop Surg,2003,11(1):25-37.
10Simon MA,Limb salvage for osleosarcoma[J].J Bone Joint Surg(Am).1988,70(2):307-310.
1Costa L. Bisphosphonates:reducing the risk of skeletal complications from bone metastasis[J].{H}BREAST,2007,(03):S16-S20.
2Chengwang,Jingwang,Han jiang. In vitro study on apoptosis induced by strontium-89in human breast carcinoma cell[J].Biomedicine and Biotechnology,2011,(09):1155-1162.
3Wenjie zhang,Weiwei zhao,Zhiyun jia. Strontium-89therapy for the treatment of huge osseous metastases in prostate carcinoma:A case report[J].Exp Ther Med,2013,(02):608-610.
4Tomasz Skóra,Teresa kowalska,Krystyna zawia. Ef-fectiveness of radioisotope therapy in bone metastases,Based on personal experience[J].Published online,2012,(03):201-205.
5Howard S. Smith,Intikhab mohsin. Painful boney metastases[J].Korean J Pain,2013,(03):223-241.
6Finlay IG,Mason MD,Shelley M. Radioisotopes for the palliation of metastatic bone cancer:a systematic review[J].{H}LANCET ONCOLOGY,2005.40-392.
